AR119018A1 - Inhibidores de proteína quinasas dependientes de adn - Google Patents

Inhibidores de proteína quinasas dependientes de adn

Info

Publication number
AR119018A1
AR119018A1 ARP200101492A ARP200101492A AR119018A1 AR 119018 A1 AR119018 A1 AR 119018A1 AR P200101492 A ARP200101492 A AR P200101492A AR P200101492 A ARP200101492 A AR P200101492A AR 119018 A1 AR119018 A1 AR 119018A1
Authority
AR
Argentina
Prior art keywords
dna
alkyl
halogen
protein kinase
kinase inhibitors
Prior art date
Application number
ARP200101492A
Other languages
English (en)
Spanish (es)
Inventor
changhe Qi
Honchung Tsui
Qingbei Zeng
Zhenfan Yang
Xiaolin Zhang
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of AR119018A1 publication Critical patent/AR119018A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP200101492A 2019-05-27 2020-05-27 Inhibidores de proteína quinasas dependientes de adn AR119018A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2019088573 2019-05-27

Publications (1)

Publication Number Publication Date
AR119018A1 true AR119018A1 (es) 2021-11-17

Family

ID=73551904

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101492A AR119018A1 (es) 2019-05-27 2020-05-27 Inhibidores de proteína quinasas dependientes de adn

Country Status (12)

Country Link
US (1) US12630565B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976624A4 (cg-RX-API-DMAC7.html)
JP (1) JP7696834B2 (cg-RX-API-DMAC7.html)
KR (1) KR102961371B1 (cg-RX-API-DMAC7.html)
CN (1) CN113924305A (cg-RX-API-DMAC7.html)
AR (1) AR119018A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020281332B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021023824A8 (cg-RX-API-DMAC7.html)
CA (1) CA3137598A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021014455A (cg-RX-API-DMAC7.html)
TW (1) TWI899080B (cg-RX-API-DMAC7.html)
WO (1) WO2020238900A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021213460A1 (zh) * 2020-04-23 2021-10-28 山东轩竹医药科技有限公司 三并环类激酶抑制剂
CN114634521A (zh) * 2020-12-15 2022-06-17 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
TW202241901A (zh) * 2020-12-21 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮衍生物、其製備方法及其在醫藥上的應用
CN114656486B (zh) * 2020-12-22 2023-09-19 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
WO2022148354A1 (zh) * 2021-01-05 2022-07-14 山东轩竹医药科技有限公司 多环类激酶抑制剂
WO2022177302A1 (ko) * 2021-02-17 2022-08-25 보령제약 주식회사 Dna-pk 억제 활성을 갖는 피리미딘-융합 고리 화합물 및 이의 용도
CN116023394B (zh) * 2021-10-25 2025-08-12 山东轩竹医药科技有限公司 三环类激酶抑制剂的晶型
CN116023393B (zh) * 2021-10-25 2025-08-12 山东轩竹医药科技有限公司 三环类激酶抑制剂的晶型
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ck12抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CA3245866A1 (en) * 2022-03-14 2023-09-21 Huyabio International, Llc Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof
CN117003754B (zh) * 2022-04-28 2025-07-25 腾讯科技(深圳)有限公司 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
CN115322209B (zh) * 2022-07-19 2023-06-20 湖北理工学院 作为dna-pk抑制剂的三并环化合物
CN116239610B (zh) * 2023-02-23 2024-01-16 遵义医科大学珠海校区 一种嘧啶衍生物及其制备方法与在制备抗肿瘤药物中的应用
EP4720069A4 (en) * 2023-07-21 2026-07-22 Wei Zhong Substituted 2-AMINO-9-(3,3-DIFLOOROPIPERIDIN-4-YL)-7,9-DIHYDRO-8H-PURIN-8-ONE COMPOUNDS AND THEIR USE IN CANCER TREATMENT
WO2025179188A1 (en) * 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
JP5190271B2 (ja) * 2005-01-14 2013-04-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としての5員の環付加複素環式ピリミジン
ES2345997T3 (es) * 2005-01-14 2010-10-07 Janssen Pharmaceutica Nv Pirazolopiramidinas como inhibidores de las quinasas del ciclo celular.
KR20070104936A (ko) 2005-02-16 2007-10-29 아스트라제네카 아베 화합물
JP2006241089A (ja) * 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
EA022120B1 (ru) 2009-10-20 2015-11-30 Целльзом Лимитид Аналоги гетероциклил пиразолопиримидина в качестве ингибиторов jak
WO2011106168A1 (en) * 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
US20130035336A1 (en) * 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
WO2011134831A1 (en) 2010-04-30 2011-11-03 Cellzome Limited Pyrazole compounds as jak inhibitors
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
JP2013534233A (ja) * 2010-08-20 2013-09-02 セルゾーム リミティッド 選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
KR20140063700A (ko) 2011-09-20 2014-05-27 셀좀 리미티드 키나제 억제제로서의 피라졸로[4,3-c]피리딘 유도체
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
RS62649B1 (sr) * 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
WO2015115673A1 (en) * 2014-01-31 2015-08-06 Ono Pharmaceutical Co., Ltd. Fused imidazole compounds
DK3558997T3 (da) * 2016-12-20 2021-04-19 Astrazeneca Ab Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
JP7230053B2 (ja) 2017-12-05 2023-02-28 オスコテック インコーポレイテッド Lrrk2阻害剤としてのピロロ(ピラゾロ)ピリミジン誘導体
TWI820146B (zh) 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
CN110885331B (zh) 2018-09-11 2021-07-09 中国药科大学 一种6-氨基-1H-吡唑并[3,4-d]嘧啶类JAK激酶抑制剂的制备与应用

Also Published As

Publication number Publication date
AU2020281332A8 (en) 2021-11-18
JP2022534261A (ja) 2022-07-28
BR112021023824A8 (pt) 2023-02-28
AU2020281332A1 (en) 2021-11-04
US12630565B2 (en) 2026-05-19
AU2020281332B2 (en) 2026-04-02
EP3976624A4 (en) 2023-06-14
TW202110849A (zh) 2021-03-16
US20220242884A1 (en) 2022-08-04
BR112021023824A2 (pt) 2022-01-04
KR20220027062A (ko) 2022-03-07
CN113924305A (zh) 2022-01-11
CA3137598A1 (en) 2020-12-03
JP7696834B2 (ja) 2025-06-23
EP3976624A1 (en) 2022-04-06
TWI899080B (zh) 2025-10-01
KR102961371B1 (ko) 2026-05-06
WO2020238900A1 (en) 2020-12-03
MX2021014455A (es) 2022-01-06

Similar Documents

Publication Publication Date Title
AR119424A1 (es) Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parp
AR119728A1 (es) Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR106053A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer
AR102204A1 (es) Compuestos derivados de amino-alquilbenzotiazepinas
AR092269A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR110400A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
AR116315A1 (es) Compuestos de triazolo-pirimidina y usos de los mismos
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR109709A1 (es) Inhibidores de la fosfatidilinositol 3-quinasa
AR094704A1 (es) Compuestos y composiciones como degradantes selectivos del receptor de estrógeno
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR110405A1 (es) Compuestos
AR112283A1 (es) Uso de derivados de aminoalquilbenzotiazepina
AR100645A1 (es) Derivados de pirazolo-pirimidina
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR101196A1 (es) Compuestos de pirimidina sustituidos
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR104512A1 (es) Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap)
AR085750A1 (es) Derivados de pirazolo-pirimidina
AR109108A1 (es) Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2
AR105975A1 (es) Sulfonamidas tricílicas limitadas heterocíclicas como agentes contra el cáncer